Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies.
Large randomized placebo-controlled trials have demonstrated that cholesterol lowering with statin therapy reduces the incidence of adverse cardiac events. Smaller angiographic studies have shown that coronary artery disease progression can be slowed and, in some cases, reversed by cholesterol-lowering interventions. These anatomical changes, however, are small and occur too slowly to account for the early clinical benefit. Current evidence suggests that plaque stabilization is the most important mechanism, by which cholesterol-lowering therapy reduces both the incidence of adverse cardiac events and coronary artery disease progression.
Archbold
R A
RA
Department of Cardiology, London Chest Hospital, UK.
Timmis
A D
AD
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D000924:Anticholesteremic Agents